Addressing everything from minor cuts and abrasions to skin rashes and muscle aches, the first aid category is doing well — sales of first-aid treatments are up 5.5% to $1.4 billion for the 52 weeks ended June 14 across total U.S. multi-outlets, according to IRI, and the larger accessories category — including heat/ice packs — is up 7.2% to $1.8 billion.
When Procter & Gamble line extended its NyQuil brand identity into the sleep care aisle with the launch of ZzzQuil, the company did more than raise a few eyebrows. That launch awoke an entire category.
Sleeping remedy sales reached $446.3 million on 6.5% growth for the 52 weeks ended June 14 across total U.S. multi-outlets, according to IRI. And while the products sold may help consumers sleep at night, the category still is contributing a steady flow of dollars to OTC coffers.
Overall, there were $8.7 billion in sales of cough, cold and allergy products for the 52 weeks ended June 14 across U.S. multi-outlets, according to IRI, and allergy remedies are driving that sales bus.
OTC buyers sniffing out the next big opportunity within VMS may need only go as far as their nose. Piping Rock Health Products, led by NBTY cofounder Scott Rudolph, is bringing aromatherapy to the mass market with its new Nature’s Truth brand.
Sales of vitamins within U.S. multi-outlets were up 3.2% to $6.7 billion for the 52 weeks ended June 14 , according to IRI, with no signs of slowing down. Gummy vitamins continue to trend within the multivitamin space, overall sales of which were up 2% to $1.7 billion.
Since the launch of Nexium 24HR in May of 2014, the brand has generated approximately $300 million, “making it one of the largest and most successful Rx-to-OTC switches,” Ian Read, Pfizer chairman and CEO, recently told analysts.
The big story in the digestives space continues to be the switch and launch of Pfizer’s Nexium 24HR. For the 52 weeks ended June 14, sales of Nexium 24HR across total U.S. multi-outlets reached $278.7 million and are still climbing, according to IRI.
Tylenol has retaken the OTC pain relief aisle with a vengeance. The brand is close to reclaiming the top spot among internal analgesic tablets behind Aleve and Advil and is growing at a 10% rate on a dollar base of more than $250 million.